# CJC-1295: Research Overview — NXT LVL Peptides > A literature summary of CJC-1295, a long-acting GHRH analog studied for sustained GH and IGF-1 elevation. Mechanism, DAC vs no-DAC pharmacology, cited findings, and safety cautions. A modified growth-hormone-releasing hormone analog, built to hold GH and IGF-1 elevated for days instead of minutes. ## The short version CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) — the signal the brain sends to the pituitary gland to release growth hormone (GH). GH then tells the liver to make IGF-1, a hormone that drives tissue growth and repair. Together, GH and IGF-1 are called the GH axis. Native GHRH breaks down in minutes. CJC-1295 does not. Four amino-acid swaps make it resistant to the enzyme that normally clears it. One version, called DAC, adds a chemical arm that latches onto a blood protein called albumin. That arm stretches its action from minutes to days. CJC-1295 is not approved for human use. It is sold as a research chemical. This page reports what the published studies found, not a recommendation. No dose appears here except the ones researchers used in a trial. ## What it is CJC-1295 is built on the first 29 amino acids of human GHRH, hGRF(1-29). Four substitutions stabilize its shape and block the enzyme dipeptidyl peptidase-IV (DPP-IV) from cutting it apart early. The DAC form ('Drug Affinity Complex') adds a linker to the last amino acid. That linker binds a cysteine on serum albumin, the most common protein in blood. Once attached, CJC-1295 rides albumin's long half-life instead of its own. The no-DAC form, sometimes sold as 'Modified GRF 1-29,' skips this step. It keeps the four substitutions but clears fast — minutes, not days. These are two different molecules with two different exposure profiles. Confusing them changes the safety picture entirely. ## How it works CJC-1295 binds the GHRH receptor on somatotroph cells in the anterior pituitary. That receptor triggers a cAMP signaling cascade, which drives the pituitary to synthesize and release GH. The GH release stays pulsatile even under constant CJC-1295 exposure — the body's natural rhythm of GH secretion is not flattened into a steady drip [5]. GH then reaches the liver, where it stimulates IGF-1 production. IGF-1 is the messenger most directly tied to tissue growth, repair, and the body-composition effects associated with GH-axis stimulation. ## What the research shows A 2025 review in a major endocrinology journal frames CJC-1295 within the broader GHRH-analog class, covering receptor signaling and the rationale for long-acting design [1]. CJC-1295 was first identified analytically — by mass spectrometry — as the active compound in a seized, unlabeled 'GHRH' product used in an anti-doping investigation, not discovered through a drug-development program aimed at consumers [2]. In 11 healthy men, CJC-1295 shifted several serum proteins, including one that tracked linearly with IGF-1 — a candidate biomarker for GH-axis activation [3]. The core human pharmacology data come from a 2006 dose-ranging study: single doses of 30 or 60 micrograms per kilogram raised mean GH 2- to 10-fold for six days or more, and IGF-1 1.5- to 3-fold for 9 to 11 days. After repeated dosing, IGF-1 stayed elevated for up to 28 days. The estimated half-life was 5.8 to 8.1 days [4]. A companion study in men aged 20 to 40 found trough GH rose roughly 7.5-fold, mean GH rose about 46%, and IGF-1 rose about 45% — with the normal pulsatile pattern of GH release intact [5]. ## Reported effects, cautions & safety *Reported benefits (anecdotal, not clinical evidence):* Deeper sleep is the most common report — often the first change users notice, sometimes within a week. That tracks with known biology: GH release peaks during deep sleep. Faster recovery from training, gradual fat loss around the midsection, and a leaner look with better muscle retention are also frequently described. Reports of more energy and sharper focus are less consistent — some notice both, others neither. *Reported adverse effects (anecdotal, not clinical evidence):* Water retention and puffiness are the most common complaint, described as more pronounced with the long-acting DAC form. Tingling or numbness in the hands, injection-site redness, and — less often — flushing, fatigue, headache, and increased appetite are also reported. None of this comes from a controlled trial; all of it is self-reported and unverified. *Cited safety cautions:* CJC-1295 has never cleared a large or long-term human trial [4]. Sustained GH and IGF-1 elevation raises a mechanism-based cancer concern, since IGF-1 is linked epidemiologically to certain cancers — an association, not proof of causation. Fluid retention is a direct consequence of GH's effect on the kidneys, and the same mechanism plausibly explains reported nerve tingling. GHRH-analog stimulation can reduce insulin sensitivity [12]. FDA briefing materials for a 2024 compounding committee flagged immunogenicity concerns for this class [1]. The DAC and no-DAC forms are pharmacokinetically distinct, and confusing them changes the exposure profile entirely [8]. CJC-1295 is prohibited in sport at all times under WADA rules. ## Where it fits in the GH axis CJC-1295 is the long-acting GHRH engine on this desk. Paired with a short-pulse GHRP like ipamorelin, its background elevation is designed to amplify a distinct hunger-driven GH spike — see [CJC-1295 / Ipamorelin](/cjc1295-ipamorelin). Against [tesamorelin](/tesamorelin), the lead compound here, CJC-1295 is the research-chemical counterpart to an FDA-approved GHRH analog with a real clinical trial record. Reading all three side by side clarifies what a GHRH signal alone does, what a ghrelin-pathway partner adds, and what a regulatory-approved comparator looks like. See the [comparison page](/compare). ![CJC-1295 research illustration — abstract endocrine-signaling motifs in indigo and violet](/images/cjc-1295.webp) --- A research digest on GH-axis peptides — it reports what the studies show, and stops there. No clinic. No sourcing.